Medicines (MDCO) Rating Increased to Sell at BidaskClub

Medicines (NASDAQ:MDCO) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Wednesday.

A number of other equities research analysts also recently weighed in on MDCO. Zacks Investment Research raised Medicines from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. ValuEngine raised Medicines from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Oppenheimer reaffirmed a “buy” rating on shares of Medicines in a report on Thursday, March 22nd. Jefferies Group reaffirmed a “buy” rating and set a $47.00 price objective on shares of Medicines in a report on Friday, February 23rd. Finally, JPMorgan Chase reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Medicines in a report on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $50.00.

MDCO stock opened at $32.20 on Wednesday. Medicines has a twelve month low of $31.57 and a twelve month high of $32.21. The stock has a market cap of $2.36 billion, a P/E ratio of -3.83 and a beta of 0.67. The company has a debt-to-equity ratio of 9.70, a quick ratio of 2.52 and a current ratio of 2.56.

Medicines (NASDAQ:MDCO) last released its earnings results on Wednesday, April 25th. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.03. Medicines had a negative return on equity of 609.97% and a negative net margin of 1,109.21%. The business had revenue of $7.71 million for the quarter, compared to the consensus estimate of $9.21 million. During the same period last year, the business earned ($1.05) earnings per share. The firm’s revenue for the quarter was down 55.8% compared to the same quarter last year. sell-side analysts predict that Medicines will post -3.51 earnings per share for the current fiscal year.

In other Medicines news, Director William Crouse sold 7,500 shares of Medicines stock in a transaction that occurred on Wednesday, March 21st. The stock was sold at an average price of $32.26, for a total transaction of $241,950.00. Following the sale, the director now directly owns 60,633 shares of the company’s stock, valued at $1,956,020.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Armin M. Kessler sold 20,000 shares of Medicines stock in a transaction that occurred on Monday, April 16th. The shares were sold at an average price of $28.71, for a total transaction of $574,200.00. The disclosure for this sale can be found here. 8.22% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC raised its stake in shares of Medicines by 33.8% in the fourth quarter. SG Americas Securities LLC now owns 7,145 shares of the company’s stock valued at $195,000 after acquiring an additional 1,805 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Medicines in the fourth quarter valued at approximately $202,000. Elkfork Partners LLC bought a new position in shares of Medicines in the fourth quarter valued at approximately $214,000. Xact Kapitalforvaltning AB bought a new position in shares of Medicines in the fourth quarter valued at approximately $218,000. Finally, Teza Capital Management LLC bought a new position in shares of Medicines in the first quarter valued at approximately $342,000.

Medicines Company Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

Analyst Recommendations for Medicines (NASDAQ:MDCO)

Receive News & Ratings for Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply